サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1760565

不活化インフルエンザワクチンの世界市場レポート 2025年

Inactivated Influenza Vaccine Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.89円
不活化インフルエンザワクチンの世界市場レポート 2025年
出版日: 2025年07月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

不活化インフルエンザワクチン市場規模は、今後数年間で力強い成長が見込まれます。2029年には99億9,000万米ドルに成長し、CAGRは8.5%となります。予測期間の成長は、4価ワクチン需要の高まり、予防接種プログラムの拡大、パンデミック対策への関心の高まり、ワクチン製造技術の進歩、ワクチンへの世界のアクセスの増加などに起因すると考えられます。この間の主な動向としては、細胞ベースのワクチン製造へのシフト、アジュバント製剤の採用拡大、インフルエンザワクチンとCOVID-19ブースターの統合、新興市場での需要拡大、個別化ワクチン戦略の開発などが挙げられます。

政府のワクチン接種プログラムの成長は、不活化インフルエンザワクチン市場を大きく押し上げています。公衆衛生に対する意識が高まるにつれ、各国政府は予防接種への取り組みを強化し、ワクチン需要の拡大やより利用しやすい予防接種サービスの提供につながっています。これらのプログラムは、ハイリスクグループに不活化インフルエンザワクチンを無料または補助金付きで提供し、ワクチン接種を広く普及させ、インフルエンザの季節的負担を軽減する上で重要な役割を果たしています。例えば、2023年12月、英国の国民保健サービス（NHS）は、特に十分なサービスを受けていない、社会から疎外されたコミュニティへの予防接種普及活動を改善することを目的とした、新しい予防接種戦略を導入しました。この戦略は、予防接種の受けやすさを拡大し、公衆衛生をさらに促進することを目的としており、不活化インフルエンザワクチン市場の成長を促進すると期待されています。

不活化インフルエンザワクチン市場の主要企業は、4価ワクチンの開発にますます力を入れています。これらのワクチンは、4つの異なるインフルエンザ・ウイルス株を防御するように設計されており、より広範な防御を提供し、ワクチンの有効性を向上させています。例えば、2025年2月、インドを拠点とする製薬会社Zydus Lifesciences社は、4つのインフルエンザ・ウイルス株に対する予防効果を提供する4価の不活化インフルエンザワクチンであるVaxiFlu-4を発売しました。このワクチンは、インフルエンザA型とB型の両方をカバーすることで、ワクチンのミスマッチのリスクを軽減し、季節性インフルエンザの流行に対する予防効果を高めるとともに、地域の疫学的動向に合わせて免疫反応を調整します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界不活化インフルエンザワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の不活化インフルエンザワクチン市場：成長率分析
  • 世界の不活化インフルエンザワクチン市場の実績：規模と成長、2019～2024年
  • 世界の不活化インフルエンザワクチン市場の予測：規模と成長、2024～2029年、2034年
  • 世界不活化インフルエンザワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の不活化インフルエンザワクチン市場：ワクチンの種類別、実績と予測、2019～2024年、2024～2029年、2034年
  • 三価不活化インフルエンザワクチン（TIIV）
  • 四価不活化インフルエンザワクチン（QIIV）
  • 世界の不活化インフルエンザワクチン市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
  • 小児
  • 青年期
  • 成人
  • 高齢者
  • 世界の不活化インフルエンザワクチン市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 公衆衛生クリニック
  • 世界の不活化インフルエンザワクチン市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • ヘルスケア提供者
  • 個人
  • 政府機関
  • 製薬会社
  • 世界の不活化インフルエンザワクチン市場：三価不活化インフルエンザワクチン（TIIV）、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 卵ベースの三価不活化インフルエンザワクチン
  • 細胞ベースの三価不活化インフルエンザワクチン
  • アジュバント添加三価不活化インフルエンザワクチン
  • 高用量三価不活化インフルエンザワクチン
  • 世界の不活化インフルエンザワクチン市場：四価不活化インフルエンザワクチン（QIIV）、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 卵ベースの四価不活化インフルエンザワクチン
  • 細胞ベースの四価不活化インフルエンザワクチン
  • アジュバント添加四価不活化インフルエンザワクチン
  • 組み換え四価不活化インフルエンザワクチン
  • 小児四価不活化インフルエンザワクチン

第7章 地域別・国別分析

  • 世界の不活化インフルエンザワクチン市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の不活化インフルエンザワクチン市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 不活化インフルエンザワクチン市場：競合情勢
  • 不活化インフルエンザワクチン市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Abbott Laboratories
  • Novartis International
  • GlaxoSmithKline plc
  • Viatris Inc.
  • CSL
  • Zydus Lifesciences Limited
  • Sinovac Biotech Ltd.
  • Bharat Biotech International Limited
  • Dalian Aleph Biomedical Co. Ltd.
  • Hualan Biological Bacterin Co. Ltd
  • Changchun Biological
  • Jiangsu gdk Biotechnology Co., Ltd.
  • KM Biologics
  • JoinHub Pharma
  • Pharmika India Private Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 不活化インフルエンザワクチン市場、2029年：新たな機会を提供する国
  • 不活化インフルエンザワクチン市場、2029年：新たな機会を提供するセグメント
  • 不活化インフルエンザワクチン市場、2029年：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35442

Inactivated influenza vaccines are flu vaccines that contain viruses that have been killed or inactivated. These vaccines stimulate the immune system to produce antibodies against the influenza virus and are administered via injection to help prevent seasonal influenza infections.

The main types of vaccines in the inactivated influenza vaccine market include the trivalent inactivated influenza vaccine (TIIV) and the quadrivalent inactivated influenza vaccine (QIIV). The trivalent inactivated influenza vaccine contains three inactivated virus strains two influenza A strains and one influenza B strain to provide protection against seasonal influenza. These vaccines are used across various age groups, including children, adolescents, adults, and the elderly, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and public health clinics. End users include healthcare providers, individuals, government organizations, and pharmaceutical companies.

The inactivated influenza vaccine market research report is one of a series of new reports from The Business Research Company that provides inactivated influenza vaccine market statistics, including inactivated influenza vaccine industry global market size, regional shares, competitors with an inactivated influenza vaccine market share, detailed inactivated influenza vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the inactivated influenza vaccine industry. This inactivated influenza vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inactivated influenza vaccine market size has grown strongly in recent years. It will grow from$6.62 billion in 2024 to $7.21 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth during the historic period can be attributed to increased seasonal influenza outbreaks, government vaccination campaigns, a rising elderly population, improved public health awareness, and the expansion of healthcare infrastructure.

The inactivated influenza vaccine market size is expected to see strong growth in the next few years. It will grow to$9.99 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to the rising demand for quadrivalent vaccines, the expansion of immunization programs, a growing focus on pandemic preparedness, technological advancements in vaccine production, and increasing global access to vaccines. Key trends during this period include a shift toward cell-based vaccine production, the growing adoption of adjuvanted formulations, the integration of influenza vaccines with COVID-19 boosters, rising demand in emerging markets, and the development of personalized vaccine strategies.

The growth of government vaccination programs is significantly boosting the inactivated influenza vaccine market. As public health awareness increases, governments are enhancing their immunization efforts, leading to greater demand for vaccines and more accessible immunization services. These programs play a critical role in providing free or subsidized inactivated influenza vaccines to high-risk groups, ensuring widespread vaccine coverage, and reducing the seasonal burden of influenza. For example, in December 2023, the UK's National Health Service (NHS) introduced a new vaccination strategy aimed at improving immunization outreach, particularly to underserved and marginalized communities. This strategy is designed to expand vaccination accessibility and further promote public health, which in turn is expected to drive growth in the inactivated influenza vaccine market.

Leading companies in the inactivated influenza vaccine market are increasingly focusing on the development of quadrivalent vaccines. These vaccines are designed to protect against four distinct strains of the influenza virus, offering broader protection and improving vaccine efficacy. For example, in February 2025, Zydus Lifesciences, an India-based pharmaceutical company, launched VaxiFlu-4, a quadrivalent inactivated influenza vaccine that provides protection against four strains of the flu virus. By covering both influenza A and B strains, this vaccine reduces the risk of vaccine mismatch and enhances protection against seasonal flu outbreaks, while also tailoring immune responses to regional epidemiological trends.

In July 2024, GSK plc, a UK-based pharmaceutical company, expanded its capabilities in mRNA vaccine development by acquiring the full rights to develop, manufacture, and commercialize mRNA-based influenza and COVID-19 vaccines from CureVac N.V. for an undisclosed amount. This acquisition allows GSK to leverage CureVac's advanced mRNA research to improve seasonal flu vaccines and boost pandemic preparedness strategies. CureVac, a Germany-based biotechnology company, specializes in mRNA-based therapeutics, including vaccines for influenza and cancer immunotherapy.

Major players in the inactivated influenza vaccine market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis International, GlaxoSmithKline plc, Viatris Inc., CSL, Zydus Lifesciences Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Dalian Aleph Biomedical Co. Ltd., Hualan Biological Bacterin Co. Ltd, Changchun Biological, Jiangsu gdk Biotechnology Co., Ltd., KM Biologics, JoinHub Pharma, and Pharmika India Private Limited.

North America was the largest region in the inactivated influenza vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated influenza vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the inactivated influenza vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The inactivated influenza vaccine market consists of sales of adjuvanted inactivated influenza vaccines, preservative-free inactivated influenza vaccines, cell-based inactivated influenza vaccines, egg-based inactivated influenza vaccines, pediatric inactivated influenza vaccines, high-dose inactivated influenza vaccines for older adults, prefilled syringe vaccines, and multidose vial vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inactivated Influenza Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inactivated influenza vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inactivated influenza vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inactivated influenza vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type Of Vaccine: Trivalent Inactivated Influenza Vaccine (TIIV); Quadrivalent Inactivated Influenza Vaccine (QIIV)
  • 2) By Application: Children; Adolescence; Adults; Elderly
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Public Health Clinics
  • 4) By End-User: Healthcare Providers; Individuals; Government Organizations; Pharmaceutical Companies
  • Subsegments:
  • 1) Trivalent Inactivated Influenza Vaccine (TIIV): Egg-based Trivalent Inactivated Influenza Vaccine; Cell-based Trivalent Inactivated Influenza Vaccine; Adjuvanted Trivalent Inactivated Influenza Vaccine; High-dose Trivalent Inactivated Influenza Vaccine
  • 2) Quadrivalent Inactivated Influenza Vaccine (QIIV): Egg-based Quadrivalent Inactivated Influenza Vaccine; Cell-based Quadrivalent Inactivated Influenza Vaccine; Adjuvanted Quadrivalent Inactivated Influenza Vaccine; Recombinant Quadrivalent Inactivated Influenza Vaccine; Pediatric Quadrivalent Inactivated Influenza Vaccine
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Sanofi S.A.; AstraZeneca plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Inactivated Influenza Vaccine Market Characteristics

3. Inactivated Influenza Vaccine Market Trends And Strategies

4. Inactivated Influenza Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Inactivated Influenza Vaccine Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Inactivated Influenza Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Inactivated Influenza Vaccine Market Growth Rate Analysis
  • 5.4. Global Inactivated Influenza Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Inactivated Influenza Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Inactivated Influenza Vaccine Total Addressable Market (TAM)

6. Inactivated Influenza Vaccine Market Segmentation

  • 6.1. Global Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Trivalent Inactivated Influenza Vaccine (TIIV)
  • Quadrivalent Inactivated Influenza Vaccine (QIIV)
  • 6.2. Global Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Children
  • Adolescence
  • Adults
  • Elderly
  • 6.3. Global Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Public Health Clinics
  • 6.4. Global Inactivated Influenza Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Healthcare Providers
  • Individuals
  • Government Organizations
  • Pharmaceutical Companies
  • 6.5. Global Inactivated Influenza Vaccine Market, Sub-Segmentation Of Trivalent Inactivated Influenza Vaccine (TIIV), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Egg-based Trivalent Inactivated Influenza Vaccine
  • Cell-based Trivalent Inactivated Influenza Vaccine
  • Adjuvanted Trivalent Inactivated Influenza Vaccine
  • High-dose Trivalent Inactivated Influenza Vaccine
  • 6.6. Global Inactivated Influenza Vaccine Market, Sub-Segmentation Of Quadrivalent Inactivated Influenza Vaccine (QIIV), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Egg-based Quadrivalent Inactivated Influenza Vaccine
  • Cell-based Quadrivalent Inactivated Influenza Vaccine
  • Adjuvanted Quadrivalent Inactivated Influenza Vaccine
  • Recombinant Quadrivalent Inactivated Influenza Vaccine
  • Pediatric Quadrivalent Inactivated Influenza Vaccine

7. Inactivated Influenza Vaccine Market Regional And Country Analysis

  • 7.1. Global Inactivated Influenza Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Inactivated Influenza Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inactivated Influenza Vaccine Market

  • 8.1. Asia-Pacific Inactivated Influenza Vaccine Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inactivated Influenza Vaccine Market

  • 9.1. China Inactivated Influenza Vaccine Market Overview
  • 9.2. China Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inactivated Influenza Vaccine Market

  • 10.1. India Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inactivated Influenza Vaccine Market

  • 11.1. Japan Inactivated Influenza Vaccine Market Overview
  • 11.2. Japan Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inactivated Influenza Vaccine Market

  • 12.1. Australia Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inactivated Influenza Vaccine Market

  • 13.1. Indonesia Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inactivated Influenza Vaccine Market

  • 14.1. South Korea Inactivated Influenza Vaccine Market Overview
  • 14.2. South Korea Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inactivated Influenza Vaccine Market

  • 15.1. Western Europe Inactivated Influenza Vaccine Market Overview
  • 15.2. Western Europe Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inactivated Influenza Vaccine Market

  • 16.1. UK Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inactivated Influenza Vaccine Market

  • 17.1. Germany Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inactivated Influenza Vaccine Market

  • 18.1. France Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inactivated Influenza Vaccine Market

  • 19.1. Italy Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inactivated Influenza Vaccine Market

  • 20.1. Spain Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inactivated Influenza Vaccine Market

  • 21.1. Eastern Europe Inactivated Influenza Vaccine Market Overview
  • 21.2. Eastern Europe Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inactivated Influenza Vaccine Market

  • 22.1. Russia Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inactivated Influenza Vaccine Market

  • 23.1. North America Inactivated Influenza Vaccine Market Overview
  • 23.2. North America Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inactivated Influenza Vaccine Market

  • 24.1. USA Inactivated Influenza Vaccine Market Overview
  • 24.2. USA Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inactivated Influenza Vaccine Market

  • 25.1. Canada Inactivated Influenza Vaccine Market Overview
  • 25.2. Canada Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inactivated Influenza Vaccine Market

  • 26.1. South America Inactivated Influenza Vaccine Market Overview
  • 26.2. South America Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inactivated Influenza Vaccine Market

  • 27.1. Brazil Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inactivated Influenza Vaccine Market

  • 28.1. Middle East Inactivated Influenza Vaccine Market Overview
  • 28.2. Middle East Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inactivated Influenza Vaccine Market

  • 29.1. Africa Inactivated Influenza Vaccine Market Overview
  • 29.2. Africa Inactivated Influenza Vaccine Market, Segmentation By Type of Vaccine, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Inactivated Influenza Vaccine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Inactivated Influenza Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inactivated Influenza Vaccine Market Competitive Landscape And Company Profiles

  • 30.1. Inactivated Influenza Vaccine Market Competitive Landscape
  • 30.2. Inactivated Influenza Vaccine Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Inactivated Influenza Vaccine Market Other Major And Innovative Companies

  • 31.1. Abbott Laboratories
  • 31.2. Novartis International
  • 31.3. GlaxoSmithKline plc
  • 31.4. Viatris Inc.
  • 31.5. CSL
  • 31.6. Zydus Lifesciences Limited
  • 31.7. Sinovac Biotech Ltd.
  • 31.8. Bharat Biotech International Limited
  • 31.9. Dalian Aleph Biomedical Co. Ltd.
  • 31.10. Hualan Biological Bacterin Co. Ltd
  • 31.11. Changchun Biological
  • 31.12. Jiangsu gdk Biotechnology Co., Ltd.
  • 31.13. KM Biologics
  • 31.14. JoinHub Pharma
  • 31.15. Pharmika India Private Limited

32. Global Inactivated Influenza Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inactivated Influenza Vaccine Market

34. Recent Developments In The Inactivated Influenza Vaccine Market

35. Inactivated Influenza Vaccine Market High Potential Countries, Segments and Strategies

  • 35.1 Inactivated Influenza Vaccine Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Inactivated Influenza Vaccine Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Inactivated Influenza Vaccine Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer